- Home
- PINE vs IMRX Comparison
PINE vs IMRX Comparison
Compare PINE & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PINE | IMRX |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.0M | 313.8M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PINE | IMRX |
|---|---|---|
| Price | $19.66 | $4.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $20.10 | $17.20 |
| AVG Volume (30 Days) | 87.9K | ★ 602.8K |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 6.29% | N/A |
| EPS Growth | N/A | ★ 37.75 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $60,532,000.00 | N/A |
| Revenue This Year | $18.63 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $84.89 | ★ N/A |
| Revenue Growth | ★ 15.90 | N/A |
| 52 Week Low | $13.10 | $3.86 |
| 52 Week High | $21.99 | $10.08 |
Technical Indicators
Market Signals| Indicator | PINE | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.16 | 50.30 |
| Support Level | $19.33 | $4.82 |
| Resistance Level | $19.96 | $5.32 |
| Average True Range (ATR) | 0.34 | 0.21 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 34.30 | 22.22 |
Price Performance
Historical ComparisonAbout PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.